Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has announced that it will present clinical data from its ongoing study of Allocetra™, a macrophage reprogramming cell therapy, at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology. The conference is scheduled to take place from June 11-14, 2025, in Barcelona, Spain. The presentation will feature data from a Phase I/II trial evaluating Allocetra™ in patients with knee osteoarthritis. The therapy has shown promising results in terms of safety and efficacy, including pain reduction and improved joint function. The company has completed patient enrollment for the Phase II stage of the trial and anticipates releasing topline data by August 2025. Enlivex representatives, including CEO Dr. Oren Hershkovitz and CMO Dr. Einat Galamidi, will attend the conference to engage with stakeholders and the scientific community.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.